You are here: Industry Insights > AbbVie

News List

Unmet needs and opportunities in the cystic fibrosis market pharmaceutical-technology
July 05, 2021
The cystic fibrosis (CF) therapeutics market has a considerable number of unmet needs. GlobalData’s upcoming CF report indicates key unmet needs in this space including the lack of curative therapies, low patient adherence to treatment, limited choice ...
Rinvoq scores positive results as a maintenance therapy for ulcerative colitis pharmatimes
July 02, 2021
AbbVie’s JAK inhibitor Rinvoq met the primary and all secondary endpoints in a Phase III ulcerative colitis maintenance study, the company announced earlier this week.
AbbVie Exercises Right to Acquire TeneoOne and TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma americanpharmaceuticalreview
June 25, 2021
AbbVie and Teneobio, Inc. announced that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma ...
Jacobio Earns $20M AbbVie Milestone contractpharma
June 21, 2021
Jacobio Pharmaceuticals dosed the first two patients in the Phase 1/2a clinical trial of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respectively, triggering a $20 million milestone payment ...
Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment prnasia
June 18, 2021
Jacobio Pharmaceuticals has announced that the first two patients have been dosed in the Phase 1/2a clinical trial of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respectively ...
Zhongchao Inc. Partners with a Subsidiary of AbbVie Inc. for Medical Education Services prnasia
June 17, 2021
Zhongchao Inc., a healthcare services company offering online healthcare information, professional training and educational services, today announced the cooperation in physician education with AbbVie ...
MHRA approves Venclyxto for newly diagnosed AML pharmatimes
June 16, 2021
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AbbVie and Roche’s Venclyxto for the treatment of newly diagnosed acute myeloid leukaemia (AML).
AbbVie partners with Caraway on Parkinson’s therapeutics pharmaceutical-technology
June 11, 2021
AbbVie has signed an exclusive, collaboration and option agreement for the development and commercialisation of Caraway Therapeutics’ small molecule candidates to treat Parkinson’s disease and other related conditions.
Abbvie's 1Q Reveneus up 51% contractpharma
May 06, 2021
Aesthetics portfolio drives growth in the quarter with Botox Cosmetic sales up 45%.
AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis pharmaceutical-business-review
April 09, 2021
AbbVie has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) and SKYRIZI (risankizumab, 150 mg) to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively, for the treatment of ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page